We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

142 hedge funds and large institutions have $415M invested in Progenics Pharmaceuticals Inc in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 47 increasing their positions, 43 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more call options, than puts

Call options by funds: $2.69M | Put options by funds: $1.16M

31% more capital invested

Capital invested by funds: $317M → $415M (+$97.3M)

9% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 43

4% less funds holding

Funds holding: 148 → 142 (-6)

14% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 21

Holders
142
Holders Change
-6
Holders Change %
-4.05%
% of All Funds
3.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
47
Reduced
43
Closed
21
Calls
$2.69M
Puts
$1.16M
Net Calls
+$1.53M
Net Calls Change
+$1.82M

Top Buyers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
+$6.47M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$4.73M
3
HCMT
Highland Capital Management (Texas)
Texas
+$3.46M
4
N
Nuveen
North Carolina
+$3.06M
5
JGC
J. Goldman & Co
New York
+$1.93M

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$3.88M
2
Deutsche Bank
Deutsche Bank
Germany
-$3.7M
3
AAP
Ardsley Advisory Partners
Connecticut
-$2.92M
4
Wells Fargo
Wells Fargo
California
-$2.21M
5
Citadel Advisors
Citadel Advisors
Florida
-$2.21M
Name Holding Trade Value Shares
Change 		Change in
Stake
Canada Life
51
Canada Life
Manitoba, Canada
$712K – – –
State of Wisconsin Investment Board
52
State of Wisconsin Investment Board
Wisconsin
$711K +$12.1K +2,500 +2%
Wells Fargo
53
Wells Fargo
California
$698K -$2.21M -459,192 -80%
Goldman Sachs
54
Goldman Sachs
New York
$687K -$1.08M -224,374 -67%
Fisher Asset Management
55
Fisher Asset Management
Washington
$649K – – –
MCM
56
Moore Capital Management
New York
$617K – – –
Millennium Management
57
Millennium Management
New York
$508K -$1.11M -230,331 -74%
UBS Group
58
UBS Group
Switzerland
$507K +$207K +43,011 +110%
BFM
59
Boothbay Fund Management
New York
$441K +$345K +71,474 New
Comerica Bank
60
Comerica Bank
Texas
$418K -$28.3K -5,878 -7%
HKAM
61
Horizon Kinetics Asset Management
New York
$415K – – –
Thrivent Financial for Lutherans
62
Thrivent Financial for Lutherans
Minnesota
$409K +$8.86K +1,838 +3%
VEA
63
Virtus ETF Advisers
New York
$402K +$314K +65,214 New
AIG
64
American International Group
New York
$393K -$145 -30 -0%
TPSF
65
Texas Permanent School Fund
Texas
$355K +$530 +110 +0.2%
Manulife (Manufacturers Life Insurance)
66
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$341K -$14K -2,901 -5%
State of Tennessee, Department of Treasury
67
State of Tennessee, Department of Treasury
Tennessee
$339K +$12.2K +2,527 +5%
CS
68
Credit Suisse
Switzerland
$333K -$167K -34,600 -39%
WMSA
69
Weiss Multi-Strategy Advisers
New York
$309K +$48.2K +10,000 +25%
OC
70
Oppenheimer & Co
New York
$309K +$241K +50,000 New
RJA
71
Raymond James & Associates
Florida
$293K -$49.8K -10,336 -18%
UBS AM
72
UBS AM
Illinois
$290K +$42K +8,704 +23%
State Board of Administration of Florida Retirement System
73
State Board of Administration of Florida Retirement System
Florida
$280K – – –
TD Asset Management
74
TD Asset Management
Ontario, Canada
$262K +$205K +42,430 New
MIM
75
MetLife Investment Management
New Jersey
$257K +$45.5K +9,436 +29%
1 2
3
4 5

PGNX Hedge Fund Activity: Q2 2019 in Review

142 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q2 2019, worth a combined $415M — up 31% from $317M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of PGNX and 18 opened new positions — a net loss of 3 holders — while 43 trimmed existing stakes and 47 added.

The largest buyer was Farallon Capital Management, adding an estimated $6.47M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $3.88M sold.

  • 142 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q2 2019, down from 148 in Q1 2019.
  • Funds reported $415M of Progenics Pharmaceuticals Inc stock for Q2 2019, up 31% quarter-over-quarter.
  • 18 funds opened new Progenics Pharmaceuticals Inc positions in Q2 2019 and 21 closed out, a net change of -3 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q2 2019 was Farallon Capital Management, an estimated $6.47M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q2 2019 was Renaissance Technologies, an estimated $3.88M sold.

Based on aggregated 13F filings for Q2 2019.